Laurus Labs informs about un-audited financial results

20 Oct 2023 Evaluate

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that the Board of Directors have approved the unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and Half year ended September 30, 2023 at their meeting held on October 20, 2023, which are enclosed along with the Limited Review Reports issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company. The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE and National Stock Exchange of India: www.bseindia.com and www.nseinda.com respectively. The Board Meeting commenced at 02.00 pm and concluded at 02.40 pm.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs Share Price

570.80 3.65 (0.64%)
26-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1841.50
Dr. Reddys Lab 1355.15
Cipla 1489.20
Lupin 2181.60
Zydus Lifesciences 959.55
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.